AbbVie announces late-breaking results for SKYRIZI study

AbbVie announced new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received SKYRIZI, an IL-23 inhibitor. These moderate to severe plaque psoriasis patients previously had a suboptimal response to treatment with secukinumab or ixekizumab, both IL-17A inhibitor therapies, for at least six months before switching to risankizumab. The data were presented at a Late-Breaking Research session during the 2023 American Academy of Dermatology Annual Meeting in New Orleans, Louisiana. Findings from this phase 3b, open-label single-arm study showed that 56.3% of patients who received risankizumab, without a washout period following a suboptimal response to secukinumab or ixekizumab achieved the week 16 primary endpoint of reduced signs and symptoms of psoriasis. A suboptimal response was defined as a static Physician’s Global Assessment score of 2 or 3 and body surface area of 3% to less than10% after at least six months of treatment with secukinumab or ixekizumab. The mean duration of treatment was 2.6 years for patients receiving secukinumab, and 2.1 years for patients receiving ixekizumab. Highlights from this new aIMM 52-week analysis include: The majority of patients achieved clear or almost clear skin at the week 52 primary endpoint; Patients achieved completely clear skin at week 16 and week 52, a secondary endpoint; Patients reported no symptoms such as pain, itching, redness and burning, as shown by a Psoriasis Symptom Scale score of 0 at week 16 and week 52, a secondary endpoint; No new safety signals were observed in this analysis.